

CURRICULUM VITAE

JAMES H. FISCHER, PHARM.D., FCCP

ADDRESS Department of Pharmacy Practice
College of Pharmacy (M/C 886)
University of Illinois at Chicago
833 S. Wood Street, Room 164
Chicago, Illinois 60612
Telephone: (312) 996-5549
Fax: (312) 996-0379
E-mail: jfischer@uic.edu

PERSONAL Date of Birth November 6, 1954
Pharmacy Licensure Minnesota, Illinois

EDUCATION AND TRAINING

- 1979-81 Postdoctoral Fellowship in Neurology and Clinical Pharmacokinetics, Departments of Neurology and Clinical Pharmacology, University of Minnesota and St. Paul-Ramsey Medical Center, St. Paul, Minnesota. Under the direction of Ilo E. Leppik, M.D. and James C. Cloyd, Pharm.D.
- 1979 Doctor of Pharmacy, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.
- 1977 Bachelor of Science in Pharmacy, Summa Cum Laude, College of Pharmacy, Drake University, Des Moines, Iowa.

PROFESSIONAL EXPERIENCE

- 1999-Present Assistant Head for Research and Postgraduate Education, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois.
- 1998-1999 Interim Assistant Head for Research and Postgraduate Education, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois.
- 1991-Present Director, Clinical Pharmacokinetics Laboratory, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois.
- 1986-Present Associate Professor, Departments of Pharmacy Practice and Pharmacodynamics, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois.
- 1983-Present Assistant Professor, Department of Neurology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois.
- 1981-1991 Assistant/Associate Director, Clinical Pharmacokinetics Laboratory, College of

Pharmacy, University of Illinois at Chicago, Chicago, Illinois.

1981-Present Pharmacotherapist, Department of Hospital Pharmacy, University of Illinois Hospitals and Clinic, Chicago, Illinois.

1981-1986 Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois.

HONORS

1987 National Institute of Mental Health and Neurological Sciences of India, Visiting Professorship

1990 Elected Fellow – American College of Clinical Pharmacy

1996 Meiji College of Pharmacy, Visiting Professorship

2002 Awarded Honorary Doctor of Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo, Japan

ORGANIZATIONAL MEMBERSHIPS

American Academy of Neurology- New AEDs Assessment Work Group

American College of Clinical Pharmacy

- Chair, Fellowship Review Committee 1997-99

American Epilepsy Society

American Society for Clinical Pharmacology and Therapeutics

BIBLIOGRAPHY

Research Articles in Refereed Journals

Fischer JH, Lockman LA, Zaske DE, Kriel RL. Phenobarbital maintenance dose requirements in treating neonatal seizures. *Neurology* 1981; 31:1042-4.

Cloyd JC, Kriel RL, Fischer JH, Sawchuk RJ, Eggerth RM. Pharmacokinetics of valproic acid in children: I. Patients on multiple antiepileptic drug therapy. *Neurology* 1983; 33:185-91.

Bailie GR, Ackerman BH, Fischer JH, Solem LD, Rotschafer JR. Increased vancomycin dosage requirements in young burn patients. *J Burn Care Rehabil* 1984; 5:376-8.

Hedrick P, Fischer J, Ghaey K, Kotis D, Pharaon A, Riff L, Tolpin M, Schauf V. Piperacillin in infants and children: Variation in pharmacokinetics with clinical status. *Proceedings of the 13th International Congress of Chemotherapy*. Spitz H, Korrer K (eds). 1983; 93:11-13.

Fischer JH, Hedrick PJ, Riff LJ. Pharmacokinetics and antibacterial activity of two gentamicin products given intramuscularly. *Clin Pharm* 1984; 3:411-6.

Cloyd JC, Fischer JH, Kriel RL, Graves NM. Valproic acid pharmacokinetics in children on and off antiepileptic drugs. *Proceedings of the Second European Congress of Biopharmaceutics and Pharmacokinetics*. Aiache JM, Hirtz J (eds). Raven Press, New York 1984; 3:142-9.

Goff DA, Spunt AL, Jung D, Bellur S, Fischer JH. Absorption characteristics of three phenytoin sodium products after administration of oral loading doses. *Clin Pharm* 1984; 3:634-8.

Zell MA, Curtis RA, Troyer WA, Fischer JH. Effect of body weight on theophylline loading doses in acute obstructive airway disease. *Chest* 1985; 87:212-6.

Cloyd JC, Kriel RL, Fischer JH. Valproic acid pharmacokinetics in children: II. Discontinuation of concomitant antiepileptic drug therapy. *Neurology* 1985; 35:1623-7.

Cwik MJ, Chiou GP, Fischer JH, Tung EC, Currie BL. Quantitative determination of tolazoline in serum and urine. *Journal of Chromatogr B* 1985; 338:123-30.

Kriel RL, Fischer JH, Cloyd JC, Green KH, Fraser GL. Valproic acid pharmacokinetics in children: III. Very high dose requirements. *Pediatr Neurol* 1986; 2:202-8.

Leppik IE, Fischer JH, Kriel RL, Sawchuk RJ. Altered phenytoin clearance with febrile illness. *Neurology* 1986; 36:1367-70.

Fischer JH, West DP, Worobec SM. Evaluation of a continual compliance monitoring program for dapsone in an outpatient Hansen's disease clinic. *Int J Lepr* 1986; 54:517-24.

Aronson IK, Rumsfield JA, West DP, Alexander J, Fischer JH, Paloucek FP. Evaluation of topical metronidazole in acne rosacea. *Drug Intell Clin Pharm* 1987; 21:346-51.

Barr AN, Fischer JH, Koller WC, Spunt A, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. *Neurology* 1988; 38:84-8.

Fischer JH, Barr AN, Paloucek FP, Dorociak JV, Spunt AL. Effect of food on the serum concentration profile of enteric-coated valproic acid. *Neurology* 1988; 38:1319-22.

DelaCruz FG, Kanter MZ, Fischer JH, Leikin JB. Efficacy of individualized phenytoin sodium loading doses administered by intravenous infusion. *Clin Pharm* 1988; 7:219-24.

Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, Riff LJ. Vancomycin pharmacokinetics in patients with various degrees of renal function. *Antimicrob Agents Chemother* 1988; 32:848-52.

Raineri DL, Cwik MJ, Rodvold KA, Deyo KL, Scaros LP, Fischer JH. Stability of nizatidine in commonly used intravenous fluids and containers. *Am J Hosp Pharm* 1988; 45:1523-9.

Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL. Near total reduction in verapamil bioavailability by rifampin: electrocardiographic correlates. *Chest* 1988; 94:954-9.

Zokufa HZ, Rodvold KA, Blum RA, Riff LJ, Fischer JH, Crossley KB, Rotschafer JC. A simulation of 5 vancomycin dosing methods. *Pharmacotherapy* 1989; 9:10-6.

Zokufa HZ, Solem LD, Rodvold KA, Crossley KB, Fischer JH, Rotschafer JC. The influence of serum albumin and acid glycoprotein on vancomycin protein binding in patients with burn injuries. *J Burn Care Rehabil* 1989;10:425-8.

Danziger L, Furmaga KM, Rodvold KA, Bombeck CT, Fischer JH. Nizatidine suppression of basal gastric acid output: a comparison of two intravenous dosage regimens. *J Clin Pharmacol* 1989;29:946-52.

Jensen RC, Fischer JH, Cwik MJ. Effect of age and training status on flunixin pharmacokinetics in the thoroughbred horse. *Am J Vet Res* 1990; 51:591-4.

Distefano G, Caltabiano L, Romeo MG, Micali G, Kim LS, Fischer JH, Solomon LM, West DP. [Percutaneous absorption of drugs during the neonatal period]. *Rivista Italiana Pediatria [Italian Journal of Pediatrics]* 1990;16:381-7.

Cunningham FE, Fischer JH, Bevelle C, Cwik MJ, Jensen RC. The pharmacokinetics of methocarbamol in the thoroughbred race horse. *J Vet Pharmacol Therap* 1992; 15:96-100.

Cloyd JC, Fischer, JH, Kriel RL, Kraus DM. Valproic acid pharmacokinetics in children: IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. *Clin Pharmacol Ther* 1993; 53:22-9.

Piscitelli SC, Danziger LH, Hill C, Slajchert AA, West DP, Fischer JH. Effectiveness of a dapsone compliance program in leprosy. *Int J Dermatol* 1993; 32:206-9.

Micali G, Bhatt RH, Distefano G, Caltabiano L, Cook B, Fischer JH, Solomon LM, West DP. Evaluation of transdermal theophylline pharmacokinetics in neonates. *Pharmacotherapy* 1993;13:386-90.

Kraus DM, Fischer JH, Reitz SJ, Kecskes SA, Yeh TF, McCulloch KM, Tung EC, Cwik MJ. Alterations in theophylline metabolism during the first year of life. *Clin Pharmacol Ther* 1993;54:351-9.

Kraus DM, Hatzopoulos FK, Reitz SJ, Fischer JH. Pharmacokinetic evaluation of two theophylline dosing methods for infants. *Ther Drug Monit* 1994; 16:270-6.

Piscitelli DA, Fischer JH, Schoen MD, Hoon TJ, Bauman JL. Bioavailability of total and unbound disopyramide: implications for clinical use of the immediate and controlled-release dosage forms. *J Clin Pharmacol* 1994; 34:823-8.

Cunningham FE, Kraus DM, Brubaker L, Fischer JH. Pharmacokinetics of intravaginal metronidazole gel. *J Clin Pharmacol* 1994;34:1060-5.

Grawe JJ, Hariman RJ, Winecoff AP, Fischer JH, Bauman JL. Reversal of the electrocardiographic effects of cocaine by lidocaine. Part 2. concentration-effect relationships. *Pharmacotherapy* 1994; 14:704-11.

Cunningham FE, Rogers S, Fischer JH, Jensen RC. The pharmacokinetics of dexamethasone in the thoroughbred racehorse. *J Vet Pharmacol Therap* 1996; 19: 68-71.

Marchetti A, Magar R, Fischer J, Sloan E, Fischer P. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx^R) versus intravenous phenytoin (Dilantin^R) in hospital emergency departments. *Clinical Therapeutic* 1996; 18:953-66.

Fischer JH, Cwik MJ, Luer MS, Sibley CB, Deyo KL. Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes. *Ann Pharmacother* 1997; 31:553-9.

Cwik MJ, Liang M, Deyo K, Andrews C, Fischer J. Simultaneous rapid high-performance liquid chromatographic determination of phenytoin and its prodrug, fosphenytoin, in human plasma and

ultrafiltrate. *J Chromatogr* 1997; 693:407-14.

Beydoun A, Fischer J, Labar DR, Harden C, Cantrell D, et al. Gabapentin monotherapy: II. a 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. *Neurology* 1997; 49:746-52.

Luer MS, Hamani C, Dujovny M, Gidal B, Cwik M, Deyo K, Fischer JH. Saturable transport of gabapentin at the blood-brain barrier. *Neurological Research* 1999;21(6):559-562.

Anderson GD, Lin Y, Fischer JH, Winn HR. Incidence of intravenous site reactions in neurotrauma patients receiving valproate or phenytoin. *Ann Pharmacother* 2000; 34:697-702.

Itokazu GS, Fischer JH, Manitpisitkul P, Harihan R, Danziger LH. Lack of effect of nizatidine-induced elevation of gastric pH on the oral bioavailability of dapsone in healthy volunteers. *Pharmacotherapy* 2002; 22(11):1416-9.

Case Reports, Monographs, Review Articles

Fischer JH, Raineri DL. Therapy Consultation: pentobarbital anesthesia for status epilepticus. *Clin Pharm* 1987; 6:601-2.

West DP, Fischer JH, McFarland ME, Cwik MJ, Micali G, Fiedler VC. Altered theophylline metabolism in psoriasis. *Drug Intell Clin Pharm* 1990; 24:464-7.

Piscitelli SC, Occhipinti DJ, Danziger LH, Hill C, West DP, Fischer JH. Therapeutic drug monitoring and pharmacist intervention in a Hansen's disease clinic. *Ann Pharmacother* 1993;27:1526-31.

Fischer JH. Emerging Concepts in antiepileptic drug therapy: a look at the new generation agents. Doylestown (PA): Health Sciences Institute CME Monograph; 1993.

Fischer JH, Barr AN, Rogers SL, Fischer PA, Trudeau VL. Lack of serious toxicity following gabapentin overdose. *Neurology* 1994; 44:982-3.

Fischer JH (editor): *The epilepsy counseling guide*. Fair Lawn(NJ):MPE Communications Inc.; 1994.

Andrews CA, Fischer JH. Gabapentin: a new agent for the management of epilepsy. *Ann Pharmacother* 1994; 28:1188-96.

Fischer JH, French J, Leppik IE. Making the most of new seizure treatments. *Patient Care* 1996; 30(1):53-83.

Allredge BK, Armstrong EP, Fischer JH, Graves NM, Ramsay RE. *Novel Strategies in the Management of Status Epilepticus: A Continuing Education Monograph*. Philadelphia (PA): Medical Education Systems, Inc.;1997.

Fischer JH. Drug Interactions with antiepileptic drugs. *Primary Care Special Edition* 1999;3:33-9; *CNS Special Edition* 1999;1:27-33; 1999 *Pocket Guide*, McMahon Publishing Group. *Annual Updates: Primary Care Special Edition* 2000; 4(1): 31-38; *CNS News Special Edition* 2000 (Dec); 2(1): 58-66; *CNS News* 2001; 3(4):39-45; *CNS News Special Edition* 2001; 3 (Dec): 30-38; 2001 *Pocket Guide*, McMahon Publishing Group; 2002 *Pocket Guide*, McMahon Publishing Group; 2004 *Pocket Guide*, McMahon Publishing.

Fischer JH, Graves NM. Guide to antiepileptic agents. CNS Special Edition 1999;1:74-9; Primary Care Special Edition 1999;3:88-91; 1999 Pocket Guide, McMahon Publishing Group.

Meek PD, Davis SN, Collins M, Gidal BE, Rutecki PA, Burstein AH, Fischer JH, Leppik IE, Ramsay RE. Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process. Arch Intern Med 1999; 159:2639-2644.

Fischer JH, Patel T. Guide to antiepileptic drugs. CNS News 2001; 3(10): 11-14; Pharmacy Practice News 2001 (Nov Suppl): 12-18; CNS News Special Edition 2001; 3 (Dec): 101-107; 2002 Pocket Guide, McMahon Publishing Group; *Annual Updates*: CNS News 2002; 4(8) Aug: 11-14; CNS News Special Edition 2002; 4 (12) Dec: 79-82; 2003 Pocket Guide, McMahon Publishing; CNS News Special Edition 2002; 4 (12) Dec: 55-66; 2004 Pocket Guide, McMahon Publishing.

Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 2003;42(1):33-58.

Fischer JH, Habibi M. Guide to Antiepileptic Agents 2003. CNS News Special Edition 2003; 5 (Dec): 63-66; 2004 Pocket Guide, McMahon Publishing; *Annual Updates*: CNS News 2004; 6(8):19-22; 2005 Pocket Guide, McMahon Publishing Group.

Fischer JH, Habibi M. Drug Interactions with antiepileptic drugs in the elderly 2004. New York: McMahon Publishing Group; 2004. (Pocket guide)

Fischer JH, Habibi M. Guide to antiepileptic agents in the elderly. CNS News 2004; 6 (5) (May): 33-39.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WR, **Fischer JH**, Bourgeois B, Wilner A, Faught RE, Sachdeo RC, Beydoun A, Glauser TA. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62:1252-60; Epilepsia 2004; 45: 401-9.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WR, **Fischer JH**, Bourgeois B, Wilner A, Faught RE, Sachdeo RC, Beydoun A, Glauser TA. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62:1261-73; Epilepsia 2004; 45:410-423.

Research Abstracts (Limited to 1991-present)

Wilkes LC, Danziger LH, Schwed J, Itokazu G, Kale P, Resnick D, Fischer JH. Steady-state pharmacokinetics of the metronidazole and the hydroxy-metabolite in the critically ill. 12th Annual Meeting - American College of Clinical Pharmacy, Minneapolis, August, 1991.

Marcadis ML, Kraus DM, Tung EC, Young SL, McCollough KM, Fischer JH. Effect of maturation on gentamicin disposition in neonates and infants. 12th Annual Meeting - American College of Clinical

Pharmacy, Minneapolis, August, 1991.

Cunningham FE, Kraus DM, Brubaker L, Fischer JH. Enhanced bioavailability of intravaginally administered metronidazole gel. 12th Annual Meeting - American College of Clinical Pharmacy, Minneapolis, August, 1991.

Piscitelli SC, Danziger LH, Hill C, West DP, Fischer JH. Long term analysis of a dapsone compliance program in patients with Hansen's disease. 2nd Annual Winter Meeting American College of Clinical Pharmacy, February, 1992, Phoenix. *Pharmacotherapy* 1991;11:32.

Tworek DA, Schoen MD, Fischer JH, Bauman JL. Bioavailability of total and unbound disopyramide: implications for the conversion of the immediate to the controlled release dosage form. 13th Annual Meeting -American College of Clinical Pharmacy, Toronto, August, 1992. *Pharmacotherapy* 1992; 12:51.

Grawe JJ, Hariman RJ, Winecoff AP, Fischer JH, Bauman JL. Lidocaine reverses cocaine-induced slowed ventricular conduction by competitive binding. 94th Annual Meeting American Society of Clinical Pharmacology and Therapeutics, Honolulu, March 1993. *Clin Pharmacol Ther* 1993; 53:135.

Occhipinti DJ, Piscitelli SC, Hill C, Deyo K, Danziger LH, Fischer JH. Acetylation and hydroxylation of dapsone in leprosy patients: relation to toxicity. 94th Annual Meeting American Society of Clinical Pharmacology and Therapeutics, Honolulu, March 1993. *Clin Pharmacol Ther* 1993; 53:158.

Piscitelli SC, Cunningham FE, Shwed JA, Danziger LH, Rodvold KA, Fischer JH. Multiple dose evaluation of a single dose pharmacodynamic model of ranitidine. 94th Annual Meeting American Society of Clinical Pharmacology and Therapeutics, Honolulu, March 1993. *Clin Pharmacol Ther* 1993; 53:218.

Andrews CA, Turnbull TL, Paloucek FP, Delacruz FG, Fischer PA, Fischer JH. Safety and pharmacokinetics of fosphenytoin following intravenous loading dose administration. Annual Meeting of the American College of Clinical Pharmacy, St Louis, August 1994. *Pharmacotherapy* 1994; 14:367.

Occhipinti DJ, Choi A, Deyo K, Danziger LH, Fischer JH. Influence of rifampin and clarithromycin on dapsone disposition and methheoglobin concentrations. 96th Annual Meeting American Society for Clinical Pharmacology and Therapeutics, San Diego, March 1995. *Clin Pharmacol Ther* 1995; 57:163.

Fischer JH, Turnbull T, Uthman B, Wilder BJ, So E, Cascino G. Safety, tolerance and pharmacokinetics of intravenous loading doses of fosphenytoin (cerebyx7) versus dilantin7. 47th Annual Meeting of the American Academy of Neurology, Seattle, May, 1995. *Neurology* 1995; 45 (suppl 4):A202.

Fischer JH, Andrews CA, Taber JE, Hier DB, Fischer PA. Multidose evaluation of gabapentin pharmacokinetics in patients with epilepsy. 21st International Epilepsy Congress, Sydney, Australia, September 1995. *Epilepsia* 1995; 36 (suppl 3):S158.

Fischer PA, Sloan EP, Turnbull TL, Paloucek FP, Delacruz FG, Fischer JH. Safety and pharmacokinetics of intravenous loading doses of fosphenytoin for acute treatment of seizures. 21st International Epilepsy Congress, Sydney, Australia, September 1995. *Epilepsia* 1995; 36 (suppl

3):S160.

Andrews SA, Fischer PA, Fischer JF. Dose-dependent pharmacokinetics of gabapentin in patients with epilepsy. Annual Meeting of American College of Clinical Pharmacy, Washington, D.C., August 1995. *Pharmacotherapy* 1995; 15:127.

Allen FH, Runge JW, Legarda S, Maria BL, Matsuo F, Fischer JH, Kugler AR, Basson SM. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin in status epilepticus. Annual Meeting of the American Epilepsy Society, Baltimore, December, 1995. *Epilepsia* 1995; 36: 90.

Ramsay RE, Philbrook B, Fischer JH, Sloan EP, Allen FH, Runge JW. Safety and pharmacokinetics of fosphenytoin (cerebyx) compared with dilantin following rapid intravenous administration. 48th Annual Meeting of the American Academy of Neurology, San Francisco, March, 1996. *Neurology* 1996;45:A245.

Fischer JH, Allen FH, Runge J, Lagarda S, Alldredge B, Matsuo F, Kugler AR, Basson SM. Fosphenytoin (Cerebyx^R) in status epilepticus: safety, tolerance, and pharmacokinetics. 100th Annual Meeting of the American Epilepsy Society, San Francisco, December, 1996. *Epilepsia* 1996; 37:202.

Luer MS, Fischer JH, Hamani C, Gidal B, Dujovny M. Dose-dependent transport of gabapentin at the blood-brain barrier. Annual Meeting of the American Epilepsy Society, San Francisco, December, 1996. *Epilepsia* 1996; 37: 22.

Fischer JH, Andrews CO, Fischer PA, Luer MS, Charbel FT. Diurnal variations in the pharmacokinetics of gabapentin. 22nd International Epilepsy Congress, Dublin, Ireland, July 1997. *Epilepsia* 1997 (suppl 3); 38: 33.

Hatzopoulos FK, Carlos MA, Fischer JH. Safety and pharmacokinetics of intramuscular fosphenytoin in neonates. Annual Meeting of Pediatric Academic Society, New Orleans, May 1998. *Pediatr Res* 1998;43:60A.

Patel T, Fischer P, Sloan E, Andrews C, King K, Fischer J. Cardiovascular effects of intramuscular fosphenytoin loading doses in critically ill patients. Annual Meeting of the American Epilepsy Society, Philadelphia, December 2001. *Epilepsia* 2001; 42 (suppl 7): 259.

INVITED PRESENTATIONS (*Limited to 1987-present*)

"Application of Pharmacokinetics Research to Clinical Practice", National Institute of Mental Health and Neurological Sciences of India, Bangalore, India, February 1987.

"Latest Developments in Drug Therapy for Epilepsy: New Drugs, Old Drugs, New Lessons in Effective Use", *Epilepsy Treatment Advances* 1988, Epilepsy Foundation of Greater Chicago, Chicago, IL, November 1988.

"Epilepsy: Current Medical, Vocational, Legal and Social Issues". Education and Training Program, The Institute for the Study of Developmental Disabilities, Illinois Institute for Developmental Disabilities, Chicago, IL, May, 1989.

"Design of Pharmacodynamic Studies". The ACCP Scientific Series: Research Study Design, Midwest Regional Conference, Chicago, IL, May 1990.

"Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Anticonvulsants". Madison 1990 Pharmacokinetics Conference-St. Mary's Hospital, Madison, WI, September 1990.

"Research Design Considerations for Pharmacodynamic Studies". 1st Annual Winter Meeting-American College of Clinical Pharmacy, Ft. Lauderdale, FA, February, 1991.

"Recent Advances in Antiepileptic Drug Therapy". Neurology Grand Rounds, University of Illinois at Chicago, February, 1991.

"Clinical Significance of 24 Hour Blood Pressure Control". Medicine Grand Rounds, St. Francis Medical Center, Peoria, IL, October 1991.

"Emerging Concepts in Antiepileptic Therapy: A Look at the New Generation Agents". American Society of Hospital Pharmacists Clinical Midyear Meeting-Satellite Symposium, Orlando, FA, December 1992.

"New Antiepileptic Drugs". Parke-Davis Speaker's Bureau Program Faculty Meeting, Tuscon, AZ, January 1993.

"Anticonvulsant Selection and Dosing in Status Epilepticus". Meriter Conference in Critical Care Pharmacotherapy, Middleton, WI, February 1993.

"Pharmacokinetics and Dosing of Anticonvulsants in the Adult and Pediatric Patient". Epilepsy Forum, Birmingham, AL, May 1993.

"Emerging Concepts in Antiepileptic Drug Therapy: A Look at the New Generation Agents". Illinois Pharmacist Association Annual Meeting. Rockford, IL, October 1993.

"Antiepileptic Therapy: Arrival of the Second Generation Agents". University of Toledo College of Pharmacy 26th Annual Expanding Hospital Pharmacy Services Seminar, Toledo, OH, October 1993.

"Antiepileptic Therapy: Arrival of the Second Generation Agents". Family Medicine Conference, Jackson Park Hospital, Chicago, IL, October 1993.

"Emerging Concepts in Antiepileptic Drug Therapy: A Look at the New Generation Agents". Western Michigan Society of Hospital Pharmacists, Grand Rapids, MI, November 1993.

"Antiepileptic Drug Therapy: A Focus on the Newer Agents". Mid America Chapter of the American College of Clinical Pharmacy, Kansas City, MO, September 1994.

"Antiepileptic Drug Therapy: An Update". Veterans Affairs Winter 1995 Program, College of Pharmacy Office of Continuing Education, Chicago, IL, January 1995.

ΔOverview of Antiepileptic Drug Therapy@ Meiji College of Pharmacy, Tokyo, Japan, March 1996.

ΔHepatic Metabolism of Dapsone and its Relationship to Drug Toxicity.@ Meiji College of Pharmacy, Tokyo, Japan, March 1996.

ΔPharmacokinetics and Therapeutic Drug Monitoring with the Antiepileptic Drugs.@ Toho University

Omori Hospital, Tokyo, Japan, March 1996.

ΔPharmacokinetics and Therapeutic Drug Monitoring with the Antiepileptic Drugs.@ Sagamidai Hospital, Sagamidai, Japan, March 1996.

ΔNew Frontiers in the Management of Acute Seizures@. New Management Strategies in the Care of Acute Epileptic Seizures Symposium, Medical Education Systems Inc. and Parke Davis Pharmaceuticals (sponsors), Atlanta, GA, September 1996.

ΔPharmacotherapy of Acute Seizures.@ Wisconsin Pharmacists Association-Long Term Care Section, Green Bay, WI, October 1996.

ΔPharmacotherapy of Acute Seizures@. Departments of Nursing and Pharmacy, Victoria Regional Medical Center, Victoria, TX, December 1996.

ΔAdvances in the Acute Treatment of Seizures.@ Northeastern New York Society of Health Systems Pharmacists, Albany, NY, March 1997.

ΔCerebyx: Clinical Update and Pharmacoeconomics@. Merritt-Putnam Regional Epilepsy Symposium, Parke-Davis Pharmaceuticals (sponsor), Orlando, FA, March 1997.

ΔFosphenytoin: Stability and Compatibility Update@. Merritt Putnam National Acute Seizure Management Symposium, Southern Clinical Neurological Society (sponsor), Orlando, FA, April 1997.

ΔPharmacotherapy of Acute Seizures: Focus on Fosphenytoin@. Western Michigan Society of Hospital Pharmacists Annual Spring Seminar, Grand Rapids, MI, May 1997.

ΔPharmacotherapy of Acute Seizures: Traditional Therapy and New Frontiers@. Department of Pharmacy, University of Texas Medical Center, San Antonio, TX, May 1997.

ΔPharmacotherapy of Acute Seizures: Traditional Therapy and New Frontiers@. Family Medicine Conference, Sacred Heart Hospital, Allentown, PA, June 1997.

ΔRole of Pharmacological Therapy in Status Epilepticus@. Status Epilepticus: Mechanisms and Therapeutics Symposium, Montefiore Medical Center and the University Hospital for Albert Einstein College of Medicine, New York, June 1997.

ΔFosphenytoin: Room Temperature Stability and Compatibility@. Merritt Putnam Regional Acute Seizure Management Symposium, Quebec City, Quebec, Canada, July 1997.

ΔOverview of Fosphenytoin@. Neurology Conference, Department of Neurology, Johns Hopkins Hospital, Baltimore, MD, July 1997.

ΔPharmacotherapy of Acute Seizures: Traditional Therapy and New Frontiers@. Medicine Conference, Irwin Army Hospital, Fort Riley, KS, September 1997.

ΔStability Studies for Anticonvulsant Drugs@. Promises and Pitfalls: Integrating Pre-Hospital and In-Hospital Care of Seizures. American College of Emergency Physicians Annual Meeting, San Francisco, CA, October 1997.

ΔOverview of Antiepileptic Drug Therapy in Children. @ Seizure Disorders: A Paradigm for Other Disabilities. Symposium sponsored by the Epilepsy Foundation of Greater Chicago and Oakton Community College, Lincolnwood, IL, October 1997.

ΔPharmacotherapy of Acute Seizures: Traditional Therapy and New Frontiers @. Maimonides Medical Center, Brooklyn, NY, January , 1998; Kings County Medical Center, Brooklyn, NY, January 8, 1998; , St. Luke=s-Roosevelt Medical Center, Manhattan, NY, July 15, 1998.

“Comparative Pharmacokinetics of Phenytoin and Fosphenytoin”, Emerging Concepts in Acute Seizure Management, International Meetings and Science, Ft. Lauderdale, FA, March 2003.

“Clinical Pharmacokinetics of Fosphenytoin”, Fosphenytoin: National Roundtable Consultants Meeting, Thomson Healthcare, San Francisco, CA, October 2003.

“Emerging Concepts in Acute Seizure Management”. Western New Jersey Society of Health Care Pharmacists, April 2004; Robert Wood Johnson Medical Center, July 2004.

GRANTS (*Limited to 1988-present*)

"Health services for person's with Hansen's disease in the Chicago, Illinois area". U.S. Public Health Service (contract no. 200-87-0011), original funding 1984-6, renewed 1987-92, Co-Investigator.

"Double-Blind Comparison of Three Doses of Topiramate and Placebo in Refractory Partial Epilepsy". McNeil Pharmaceuticals, 1988-89, Co-Principal Investigator with A. Barr.

"Preclinical Toxicology Studies of New Drugs". Department of Defense-U.S. Army (DAMD17-87-C-7225), 1987-90, Co-Investigator.

"Long Term Treatment with Topiramate - Open Extension Protocols YK-T, YK-P, and YLT". McNeil Pharmaceuticals, 1989-97, Co-Principal Investigator with A. Barr.

"An Open Label Multicenter Study of Gabapentin Safety and Efficacy in Epilepsy". Warner Lambert Company, 1989-93, Principal Investigator.

"Bioavailability of Intravaginal 0.75% Metronidazole Gel". Curatek Pharmaceuticals, 1989-90, Principal Investigator.

"Bioavailability evaluation of topically administered 5% spironolactone cream". G.D. Searle and Company, 1989-90, Co-Investigator.

"Comparative single and multiple dose bioavailability evaluation of intravaginal 0.75% metronidazole gel in patients with bacterial vaginosis". Curatek Pharmaceuticals, 1990, Principal Investigator.

"Master Agreement for the Clinical Evaluation of Investigational Antiepileptic Drugs". National Institute of Neurological Disorders and Stroke, National Institute of Health (MAA NIH-NINDS-91-10; NO1-NS-2341), 1992-7 (Co-Principal Investigator with D. Hier).

"Double-Blind Comparison: Intravenous Fosphenytoin vs. Dilantin". Warner Lambert Co., 1992,

C.V.- James H. Fischer

Page - 12

Principal Investigator.

"Conversion from Marketed Antiepileptic Drug Therapy to Gabapentin Monotherapy in Patients with Complex Partial or Secondarily Generalized seizures: A Double-Blind, Dose-Controlled, Multicenter Study". Parke Davis Pharmaceutical Research, Warner Lambert Company, 1992-4, Principal Investigator.

"Safety and Efficacy of Intravenous Fosphenytoin in Status Epilepticus". Parke Davis Pharmaceutical Research, Warner Lambert Company, 1993, Principal Investigator.

"Loteprednol Etabonate: Formulation Development and Evaluation". Genderm Corporation, 1992-4, Principal Investigator.

"Safety, Efficacy, and Pharmacokinetics of Extended Gabapentin Monotherapy". Parke Davis Pharmaceutical Research, Warner Lambert Company, 1993-5, Principal Investigator.

"A Multicenter, Double-Blind, Active Control Evaluation of the Efficacy and Safety of Lamotrigine Monotherapy in Patients with Partial Seizures." Burroughs Wellcome Co., 1994-5, Principal Investigator.

"Evaluation of the Efficacy and Tolerability of ucb L059 (500 and 1500 mg b.i.d. tablets) Add-On Treatment in Epileptic Patients with Partial Onset Seizures: A 38-Week Double-Blind Placebo-Controlled Parallel Group Multicenter Trial." UCB S.A. Pharma Sector, 1994-5, Co-Principal Investigator.

"A Pharmacokinetic/Bioavailability Evaluation of Topically Administered Metronidazole Cream, 0.75% and Metronidazole Lotion, 0.75% in Healthy Adult Volunteers." Galderma Laboratories, Inc., 1994-5, Principal Investigator.

"Double-Blind, Single-Dose, Parallel Group, Safety, Tolerance, and Pharmacokinetic Study of Intravenous Fosphenytoin Versus Intravenous Dilantin in Patients Requiring a Loading Dose of Phenytoin (Protocol 982-26)". Parke-Davis Pharmaceutical Research, Warner-Lambert Co., 1995, Principal Investigator.

"A Multicenter Follow-Up Study of the Safety and Efficacy of Oral 500 mg Tablets ucb L059 in Patients with Partial Onset Epileptic Seizures: A 6-Week Double-Blind Titration to 3000 mg/day, Followed by an Open Treatment Phase at Individualized Doses". UCB S.A. Pharma Sector, 1995-7, Co-Principal Investigator with D. Hier.

ΔPharmacokinetic and Pharmacodynamic Evaluation of Four Doses of a Topical Clonidine Gel, 0.1% in Normal Volunteers@. Curatek Pharmaceuticals, 1996-7, Co-Investigator.

"Cost Analysis of the Routine Use of Parenteral IM Fosphenytoin Versus IV Fosphenytoin in the Management of Seizures Within the Hospital Setting". Parke-Davis Pharmaceutical Research, Warner-Lambert Co., 1996-7, Principal Investigator.

"A Long-Term, Open-Label, Multicenter Study of the Safety and Efficacy of ucb L059 (Levetiracetam) 500 mg Tablets at Individualized Oral Doses Ranging from 1000 mg/day to 4000 mg/day in the Treatment of Epilepsy". UCB S.A. Pharma Sector, 1996-8, Co-Principal Investigator with D. Hier.

ΔDouble-Blind Comparison of Tiagabine versus Carbamazepine or Phenytoin as Adjunctive Treatment for Complex Partial Seizures@. Abbott Laboratories, 1996-7, Co-Investigator.

ΔStability and Compatibility Evaluation of the Fosphenytoin Parenteral Solution@. Parke-Davis Pharmaceuticals, Warner-Lambert Co., 1997-8, Principal Investigator.

ΔSteady-State Pharmacokinetics Following Daily Dosing with 2 and 4 mg of 0.1% Topical Clonidine Gel@. Curatek Pharmaceuticals, 1999, Principal Investigator.

ΔPregabalin BID Add-On Trial: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study in Patients with Partial Seizures.@ Parke-Davis Pharmaceuticals, Warner-Lambert Co., 1998-2000, Principal Investigator.

ΔPregabalin Open-Label Add-on Trial@. Pfizer, 1999-2004, Principal Investigator.

ΔMultiple Dose Pharmacokinetics and Relative Bioavailability of 0.05% Clonidine Gel in Healthy Adult Volunteers Following Topical Application to the Lower Legs and Flank@. Curatek Pharmaceuticals, 2000, Principal Investigator.

ΔLabetalol and Hypertension in Pregnancy: Pharmacokinetics and Pharmacodynamics@. U.S. Department of Health and Human Services/Food and Drug Administration Office of Women=s Health (233-01-0033), 2001-3, Principal Investigator with J. Hardman.

“Pharmacokinetics and Pharmacodynamics of Selected Antibiotics During Pregnancy”. U.S. Department of Health and Human Services/Food and Drug Administration Office of Women=s Health (233-02-0114), 2002-4, Co- Principal Investigator (Principal Investigator: Gloria Sarto, M.D., Ph.D., University of Wisconsin).

“FDA Contract to perform Women’s Health Studies”. FDA’s Office of Women’s Health Research Studies (223-03-8726), 2003-8, Principal Investigator.

CONSULTATIONS

- Speakers Bureau
 - Esai
 - Pfizer
 - ucb Pharma
- Editorial Board
 - DICP:The Annals of Pharmacotherapy 1982-94 (Chairman-Neurology Panel; 1984-92)
 - CNS News, McMahon Publishing
- Ad hoc Journal Reviewer- The Annals of Pharmacotherapy
 - Pharmacotherapy
 - Epilepsy Research
- Professional Advisory Boards/Consultantships
 - Epilepsy Foundation of Greater Chicago
 - U.S. and International Epilepsy Advisory Board, Parke-Davis/Pfizer
 - MediChem Pharmaceuticals/Advanced Life Sciences
 - Winston Laboratories
 - CURE (Citizen=s United for Research in Epilepsy)